49 related articles for article (PubMed ID: 7521642)
1. Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells.
Pan X; Arauz E; Krzanowski JJ; Fitzpatrick DF; Polson JB
Biochem Pharmacol; 1994 Aug; 48(4):827-35. PubMed ID: 7521642
[TBL] [Abstract][Full Text] [Related]
2. 3-isobutylmethylxanthine inhibits hepatic urea synthesis: protection by agmatine.
Nissim I; Horyn O; Nissim I; Daikhin Y; Wehrli SL; Yudkoff M
J Biol Chem; 2008 May; 283(22):15063-71. PubMed ID: 18375388
[TBL] [Abstract][Full Text] [Related]
3. Phosphodiesterase inhibitors as a new generation of antiprotozoan drugs: exploiting the benefit of enzymes that are highly conserved between host and parasite.
Seebeck T; Sterk GJ; Ke H
Future Med Chem; 2011 Aug; 3(10):1289-306. PubMed ID: 21859303
[TBL] [Abstract][Full Text] [Related]
4. Natural and Synthetic Phosphodiesterase Inhibitors in 2023: an Update on the Impact on Neurological and Psychiatric Conditions.
Ribaudo G; Gianoncelli A
Mini Rev Med Chem; 2024; 24(6):568-570. PubMed ID: 37817520
[TBL] [Abstract][Full Text] [Related]
5. Rolipram: Eotaxin and phosphodiesterase IV inhibitor versus bronchial hyper-reactivity response.
Khan HH; Assad S; Rahman MA; Niazi AK
Adv Biomed Res; 2015; 4():224. PubMed ID: 26623399
[No Abstract] [Full Text] [Related]
6. Ending Restenosis: Inhibition of Vascular Smooth Muscle Cell Proliferation by cAMP.
Smith SA; Newby AC; Bond M
Cells; 2019 Nov; 8(11):. PubMed ID: 31744111
[TBL] [Abstract][Full Text] [Related]
7. Risk of Heart Failure Hospitalization Associated With Cilostazol in Diabetes: A Nationwide Case-Crossover Study.
Wu CK; Lin JW; Wu LC; Chang CH
Front Pharmacol; 2018; 9():1467. PubMed ID: 30666197
[No Abstract] [Full Text] [Related]
8. Open-Label Phase I Clinical Study to Assess the Safety and Efficacy of Cilostazol in Patients Undergoing Internal Carotid Artery Stent Placement.
Hassan AE; Zacharatos H; Grigoryan M; Tekle WG; Khan A; Siddiq F; Rodriguez GJ; Tummala R; Jagadeesan B; Suri MFK; Qureshi AI
Interv Neurol; 2017 Mar; 6(1-2):42-48. PubMed ID: 28611833
[TBL] [Abstract][Full Text] [Related]
9. No Association Between Single-Nucleotide Polymorphism 56 (SNP56) in Phosphodiesterase 4D (PDE4D) Gene and Susceptibility to Ischemic Stroke: A Meta-Analysis of 15 Studies.
Zhang XY; Wan Q; Zhu DY
Med Sci Monit; 2016 Oct; 22():3820-3827. PubMed ID: 27759733
[TBL] [Abstract][Full Text] [Related]
10. Regulation of soluble guanylyl cyclase redox state by hydrogen sulfide.
Zhou Z; Martin E; Sharina I; Esposito I; Szabo C; Bucci M; Cirino G; Papapetropoulos A
Pharmacol Res; 2016 Sep; 111():556-562. PubMed ID: 27378567
[TBL] [Abstract][Full Text] [Related]
11. Association between phosphodiesterase 4D (PDE4D) SNP 87 and ischemic stroke: a meta-analysis.
Liang W; Zhang D; Mang J; He J; Liu H; Shao Y; Han F; Xu Z
Int J Clin Exp Med; 2015; 8(2):1715-25. PubMed ID: 25932100
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy and safety of cilostazol: a critical review of the literature.
Rogers KC; Oliphant CS; Finks SW
Drugs; 2015 Mar; 75(4):377-95. PubMed ID: 25758742
[TBL] [Abstract][Full Text] [Related]
13. Levels and values of lipoprotein-associated phospholipase A2, galectin-3, RhoA/ROCK, and endothelial progenitor cells in critical limb ischemia: pharmaco-therapeutic role of cilostazol and clopidogrel combination therapy.
Sheu JJ; Lin PY; Sung PH; Chen YC; Leu S; Chen YL; Tsai TH; Chai HT; Chua S; Chang HW; Chung SY; Chen CH; Ko SF; Yip HK
J Transl Med; 2014 Apr; 12():101. PubMed ID: 24742198
[TBL] [Abstract][Full Text] [Related]
14. Combination of cilostazol and clopidogrel attenuates rat critical limb ischemia.
Sheu JJ; Lin KC; Tsai CY; Tsai TH; Leu S; Yen CH; Chen YL; Chang HW; Sun CK; Chua S; Yang JL; Yip HK
J Transl Med; 2012 Aug; 10():164. PubMed ID: 22897925
[TBL] [Abstract][Full Text] [Related]
15. The effectiveness and safety of triple-antiplatelet treatment based on cilostazol for patients receiving percutaneous coronary intervention: a meta-analysis.
Wang P; Zhou S; Zhou R; Liu G; Tang P; He J; Ma C; He Y; Yang J
Clin Cardiol; 2012 Oct; 35(10):598-604. PubMed ID: 22585740
[TBL] [Abstract][Full Text] [Related]
16. Thrombospondin-1 inhibition of vascular smooth muscle cell responses occurs via modulation of both cAMP and cGMP.
Yao M; Roberts DD; Isenberg JS
Pharmacol Res; 2011 Jan; 63(1):13-22. PubMed ID: 20971192
[TBL] [Abstract][Full Text] [Related]
17. Triple antiplatelet therapy vs. dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: an evidence-based approach to answering a clinical query.
Singh I; Shafiq N; Pandhi P; Reddy S; Pattanaik S; Sharma Y; Malhotra S
Br J Clin Pharmacol; 2009 Jul; 68(1):4-13. PubMed ID: 19659998
[TBL] [Abstract][Full Text] [Related]
18. Expression, activity, and function of phosphodiesterases in the mature and immature ductus arteriosus.
Liu H; Manganiello V; Waleh N; Clyman RI
Pediatr Res; 2008 Nov; 64(5):477-81. PubMed ID: 18552705
[TBL] [Abstract][Full Text] [Related]
19. Suppression of arterial intimal hyperplasia by cilostamide, a cyclic nucleotide phosphodiesterase 3 inhibitor, in a rat balloon double-injury model.
Inoue Y; Toga K; Sudo T; Tachibana K; Tochizawa S; Kimura Y; Yoshida Y; Hidaka H
Br J Pharmacol; 2000 May; 130(2):231-41. PubMed ID: 10807659
[TBL] [Abstract][Full Text] [Related]
20. Calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDE1C) is induced in human arterial smooth muscle cells of the synthetic, proliferative phenotype.
Rybalkin SD; Bornfeldt KE; Sonnenburg WK; Rybalkina IG; Kwak KS; Hanson K; Krebs EG; Beavo JA
J Clin Invest; 1997 Nov; 100(10):2611-21. PubMed ID: 9366577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
